NEW YORK, Dec. 4—Eukarion said Tuesday that it had launched a collaboration with Proteome Systems and the Buck Institute for Age Research to study the proteomics of aging. The research will focus on mitochondrial oxidative stress and the role of mitochondrial dysfunction in aging.
Under the agreement, Eukarion will provide compounds that augment natural antioxidant pathways. Buck Institute researchers, led by Simon Melov, will study these drug candidates in mice. Sydney, Australia-based Proteome Systems will analyze the resulting tissue samples, create arrays, organize the data, and generate databases or other tools to characterize protein changes.
Potential revenues from any compounds developed through the partnership will be shared. Further financial terms were not disclosed.
"We know our molecules lead to extension of lifespan in C. elegans and mice," said Janet Smart, the vice president for corporate development at Eukarion. "We want to explore those changes further. We're looking for potential targets, proteins that turn out to be important in aging."
Bedford, Mass.-based Eukarion is a privately held drug development company focused on research into novel synthetic catalytic scavengers designed to inactivate oxygen radicals and other reactive oxygen species. The company develops therapeutics for age-related dermatological and neurodegenerative diseases. It recently inked an agreement with the Swiss biotech company Modex Therapeutics, which is developing a Eukarion compound for the prevention and treatment of radiation-induced skin damage.
The Buck Institute is a nonprofit, independently funded research organization based in Novato, Calif., focused on the biology of aging and age-related diseases. It has previously conducted studies with Eukarion compounds, publishing results showing anti-aging efficacy in nematodes and knockout mice.